2012-11-08 17:33:16 -

KVISTGAARD, Denmark, November 8, 2012 - Bavarian Nordic (OMX: BAVA) announced
today that Anders Hedegaard, President & CEO will present at the Jefferies 2012
Global Healthcare Conference in London on Thursday, November 15, 2012 at 4:20
p.m. GMT.

The presentation slides will subsequently be available on the company's website:
www.bavarian-nordic.com/investor

Contact
Rolf Sass Sørensen, Vice President Investor Relations & Communications
E-mail: investor@bavarian-nordic.com
Phone: +45 33 26 83 83

About Bavarian Nordic
Bavarian Nordic is a vaccine-focused biotechnology company developing and
producing novel vaccines for the treatment and prevention of life-threatening
diseases with a large unmet medical need. The company's pipeline targets cancer
and infectious diseases, and includes ten development programs. In oncology, the
company's lead program is PROSTVAC®, a therapeutic vaccine candidate for
advanced prostate cancer that is the subject of an ongoing pivotal Phase 3   trial
and is being developed under a collaboration agreement with the National Cancer
Institute. In clinical Phase 1 and Phase 2 trials, PROSTVAC® has been tested in
nearly 600 patients. In infectious diseases, the company's lead program is
IMVAMUNE®, a third-generation smallpox vaccine candidate that is being developed
and supplied for emergency use to the U.S. Strategic National Stockpile under a
contract with the U.S. Government. For more information, visit www.bavarian-
nordic.com




This announcement is distributed by Thomson Reuters on behalf of 
Thomson Reuters clients. The owner of this announcement warrants that: 
(i) the releases contained herein are protected by copyright and 
    other applicable laws; and 
(ii) they are solely responsible for the content, accuracy and 
     originality of the information contained therein. 
    
Source: Bavarian Nordic A/S via Thomson Reuters ONE
[HUG#1656200]